Pharmaceutical

Grifols prepares for late-stage plans with plasma-derived medicines in 2024

In an interview with Pharmaceutical Technology, the company’s chief scientific officer detailed the company’s upcoming 2024 plans.

Feb 28, 2024 - 18:00
Grifols prepares for late-stage plans with plasma-derived medicines in 2024
In an interview with Pharmaceutical Technology, the company’s chief scientific officer detailed the company’s upcoming 2024 plans.
Read the original article

Tags:

Previous Article

Minerva hit with FDA rejection for schizophrenia symptom drug

Next Article

Bristol Myers Squibb Expands Irish Campus with $400M Investment in Drug Manufact...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: It was a turbulent year for the business of health tech. 3 trends to watch in 2024

STAT+: It was a turbulent year for the business of heal...

Jan 2, 2024

Opinion: When should hospitals require masks?

Opinion: When should hospitals require masks?

Jun 6, 2023

Ultimovacs bags orphan drug tag for mesothelioma vaccine

Ultimovacs bags orphan drug tag for mesothelioma vaccine

Oct 9, 2023